SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Novartis Reports Sustained 144-Week Phase III Pelabresib Effects

Novartis says Phase III data show sustained effects in first-line JAK inhibitor-naïve myelofibrosis patients through 144 weeks.

Related stories